Edmp Inc. trimmed its holdings in shares of Amgen, Inc. (NASDAQ:AMGN) by 3.9% during the fourth quarter, Holdings Channel reports. The fund owned 25,382 shares of the medical research company’s stock after selling 1,020 shares during the quarter. Amgen accounts for 4.0% of Edmp Inc.’s investment portfolio, making the stock its 3rd largest holding. Edmp Inc.’s holdings in Amgen were worth $4,697,000 as of its most recent filing with the SEC.
Other hedge funds and other institutional investors have also made changes to their positions in the company. Baker Ellis Asset Management LLC acquired a new position in Amgen in the third quarter worth about $108,000. Jackson Grant Investment Advisers Inc. grew its stake in Amgen by 0.8% in the second quarter. Jackson Grant Investment Advisers Inc. now owns 641 shares of the medical research company’s stock worth $110,000 after purchasing an additional 5 shares in the last quarter. Phocas Financial Corp. acquired a new position in Amgen in the second quarter worth about $110,000. Omnia Family Wealth LLC grew its stake in Amgen by 25.3% in the second quarter. Omnia Family Wealth LLC now owns 729 shares of the medical research company’s stock worth $125,000 after purchasing an additional 147 shares in the last quarter. Finally, Salem Investment Counselors Inc. grew its stake in Amgen by 4.7% in the second quarter. Salem Investment Counselors Inc. now owns 809 shares of the medical research company’s stock worth $139,000 after purchasing an additional 36 shares in the last quarter. 78.03% of the stock is currently owned by institutional investors and hedge funds.
Amgen, Inc. (NASDAQ:AMGN) opened at $183.55 on Monday. The company has a current ratio of 5.49, a quick ratio of 5.17 and a debt-to-equity ratio of 1.35. The stock has a market capitalization of $132,259.19, a P/E ratio of 14.59, a PEG ratio of 2.19 and a beta of 1.42. Amgen, Inc. has a 52-week low of $152.16 and a 52-week high of $201.23.
Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Thursday, February 1st. The medical research company reported $2.89 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $3.03 by ($0.14). The business had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a return on equity of 30.87% and a net margin of 8.66%. The business’s quarterly revenue was down 2.7% on a year-over-year basis. During the same quarter in the prior year, the firm posted $2.89 earnings per share. research analysts anticipate that Amgen, Inc. will post 13.21 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 8th. Stockholders of record on Thursday, February 15th will be given a dividend of $1.32 per share. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 annualized dividend and a dividend yield of 2.88%. Amgen’s payout ratio is currently 205.45%.
Amgen declared that its Board of Directors has initiated a stock buyback program on Wednesday, October 25th that allows the company to buyback $5.00 billion in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Stock buyback programs are typically an indication that the company’s management believes its stock is undervalued.
A number of equities analysts recently commented on the company. Piper Jaffray Companies decreased their price target on Amgen from $194.00 to $190.00 and set an “overweight” rating for the company in a research note on Friday, February 2nd. Atlantic Securities downgraded Amgen from an “overweight” rating to a “neutral” rating and set a $187.01 price target for the company. in a research note on Monday, February 5th. Mizuho lifted their price target on Amgen from $192.00 to $200.00 and gave the stock a “buy” rating in a research note on Monday, February 12th. Oppenheimer set a $205.00 price target on Amgen and gave the stock a “buy” rating in a research note on Friday, January 5th. Finally, BMO Capital Markets lifted their price target on Amgen from $192.00 to $202.00 and gave the stock a “market perform” rating in a research note on Friday, February 2nd. Sixteen equities research analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and a consensus price target of $191.84.
In other news, EVP Sean E. Harper sold 1,525 shares of the business’s stock in a transaction that occurred on Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total transaction of $283,070.50. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Over the last quarter, insiders have sold 4,575 shares of company stock valued at $818,361. Insiders own 0.19% of the company’s stock.
Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).
Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.